sleep

ResMed cut at Oppenheimer after Lilly’s sleep apnea data

Pgiam/iStock via Getty Images Oppenheimer downgraded respiratory device maker ResMed (NYSE:RMD) to Perform from Outperform on Tuesday, citing an “air pocket” for the stock in the wake of encouraging data for Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide in obstructive sleep apnea (OSA). The maker of CPAP (continuous positive airwayContinue Reading

Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data

In: Finance

JHVEPhoto Inspire Medical Systems (NYSE:INSP) and ResMed (NYSE:RMD) are both down significantly in Monday trading, apparent casualties of positive data released after the closing bell on June 21 of Eli Lilly’s (LLY) diabetes and weight loss drug tirzepatide as a sleep apnea treatment. Inspire manufactures an implantable neurostimulation device forContinue Reading

ResMed cut at Oppenheimer after Lilly’s sleep apnea data

Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data

How Rocket Companies modernized their data science solution on AWS | Amazon Web Services

AWS and DXC collaborate to deliver customizable, near real-time voice-to-voice translation capabilities for Amazon Connect | Amazon Web Services